MACK vs. REPH, LXRX, VNDA, XOMA, AGEN, EBS, CDXS, ACHV, RIGL, and RGLS
Should you be buying Merrimack Pharmaceuticals stock or one of its competitors? The main competitors of Merrimack Pharmaceuticals include Recro Pharma (REPH), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Agenus (AGEN), Emergent BioSolutions (EBS), Codexis (CDXS), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), and Regulus Therapeutics (RGLS). These companies are all part of the "medical" sector.
Merrimack Pharmaceuticals (NASDAQ:MACK) and Recro Pharma (NASDAQ:REPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
64.0% of Merrimack Pharmaceuticals shares are held by institutional investors. Comparatively, 62.3% of Recro Pharma shares are held by institutional investors. 30.6% of Merrimack Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of Recro Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Merrimack Pharmaceuticals has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Recro Pharma has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Merrimack Pharmaceuticals received 51 more outperform votes than Recro Pharma when rated by MarketBeat users. Likewise, 66.67% of users gave Merrimack Pharmaceuticals an outperform vote while only 56.20% of users gave Recro Pharma an outperform vote.
In the previous week, Merrimack Pharmaceuticals had 1 more articles in the media than Recro Pharma. MarketBeat recorded 1 mentions for Merrimack Pharmaceuticals and 0 mentions for Recro Pharma. Merrimack Pharmaceuticals' average media sentiment score of 0.92 beat Recro Pharma's score of 0.00 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the media.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to Recro Pharma's net margin of -15.15%. Merrimack Pharmaceuticals' return on equity of -1.93% beat Recro Pharma's return on equity.
Merrimack Pharmaceuticals has higher earnings, but lower revenue than Recro Pharma. Recro Pharma is trading at a lower price-to-earnings ratio than Merrimack Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Merrimack Pharmaceuticals beats Recro Pharma on 13 of the 14 factors compared between the two stocks.
Get Merrimack Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Merrimack Pharmaceuticals Competitors List
Related Companies and Tools
